Dementia drugs evolve to ‘shift needle’ on care
LONDON: Dementia research is entering a promising new era after two drugs were shown to slow the rate of cognitive and functional decline in people living with early-stage Alzheimer’s disease.
Approved by the Therapeutic Goods Administration last year, the drugs were the first medications in Australia to go beyond symptom management and actually slow progression of the disease, which accounts for about two-thirds of the 459,000 dementia cases in Australia.
As a result, researchers say the drugs have “shifted the needle” on Alzheimer’s treatment and should pave the way for a new generation of even more effective treatments.
Rebecca Nisbet, an associate professor at the Florey Institute of Neuroscience and Mental Health in Melbourne, said: “The floodgates are now open – and we’re going to see a rapid influx of new drugs.”
The two drugs approved last year were donanemab and lecanemab.
Both drugs are laboratory-engineered antibodies that facilitate the removal of amyloid plaques in the brain – one of the hallmarks of Alzheimer’s disease – making them the first medications in Australia proved to slow the rate of cognitive decline caused by the disease.
Neither is subsidised on the Pharmaceutical Benefits Scheme or available to many patients.
“We’re very encouraged that we’ve seen a drug that has shifted the needle,” said Scott Ayton, head of dementia research at the Florey Institute.
“But these drugs need to be understood in context: people still decline on these treatments. And it’s fair to say that people were hoping that they would have a larger effect in clinical trials,” said Ayton.
In one randomised trial of more than 1700 people with early Alzheimer’s disease, known as the TRAILBLAZER-ALZ 2 trial, donanemab slowed disease progression by about four months, compared with a placebo, over 18 months of treatment.
The BMJ said this amounted to “a modest slowdown in cognitive decline”, and noted in a separate editorial on lecanemab that the “overall trial evidence tells us that successful amyloid clearance in adults with early Alzheimer’s disease has either no effect or a tiny effect on cognitive decline”.
Ayton said many patients would probably fail to notice the effect of donanemab, given it amounted to a slower rate of decline rather than an improvement in cognition.
“They’re not game changers like we’ve seen with the GLP-1 drugs, which have had a huge effect on weight loss,” he said.
The drugs can also cause brain swelling and bleeding and are prohibitively expensive for many Australians.
This is because the size of the molecules makes it difficult for them to cross the blood-brain barrier, the semi-permeable layer of cells that lines the blood vessels in the brain and spinal cord and blocks most foreign substances from crossing.
“They’re quite large in terms of drug size, [which means only] 0.1 per cent of the antibodies can get into the brain if they’re injected into the bloodstream,” said Nisbet.
This means patients have to take high doses of the drugs for enough of the antibodies to cross the blood-brain barrier and have the desired effect on the brain.
This leads to two problems: higher costs and a greater risk of side effects.
Nisbet said it costs about $80,000 to $100,000 each patient for each year of treatment in Australia – a figure that does not just cover the drugs but includes all the monitoring and diagnostic tests required to accompany the treatment, including magnetic resonance imaging (MRI) and amyloid positron emission tomography (PET) scans.
Meanwhile, in the TRAILBLAZER-ALZ 2 trial, 24 per cent of participants who took donanemab experienced brain swelling or fluid build-up around the brain, compared with just 2.1 per cent in the placebo group. Similar problems were reported with lecanemab.
“These drugs do have quite a dangerous side effect called amyloid-related imaging abnormality,” said Nisbet.
“Because they’re not really getting into the brain properly, they sit around in our blood vessels and bind to plaque formation in our bloodstream, which makes our blood vessels quite weak and leaky and can cause haemorrhaging and brain swelling.”
About 90 per cent of people with Alzheimer’s disease in Australia are excluded from the treatments. This is because the risks outweigh the benefits if people have advanced Alzheimer’s disease, a history of brain swelling or hemorrhaging, or carry two copies of the ApoE4 gene, which increases their risk of these side effects.
Still, dementia researchers are feeling more optimistic than they have in decades. After hundreds of drug trials ended in disappointment and dementia rose to become Australia’s No.1 killer, two drugs have finally been shown to (modestly) modify Alzheimer’s disease.
Plus, we now have a TGA-approved blood test, called a pTau217, that can accurately rule in or rule out Alzheimer’s disease in people with memory problems.
“We’ve now got an accurate test, and we’ve now got treatments,” said Michael Woodward, head of dementia research at The Austin Hospital in Melbourne.
“That’s something I wouldn’t have even dreamt of when I started my research career in Alzheimer’s over 30 years ago. It’s marvellous.”
The field is now focused on developing safer and more effective drugs that can clear amyloid plaques or tau protein (also linked to Alzheimer’s disease) at far lower doses than donanemab and lecanemab, which should result in fewer side effects.
“Trontinemab is the one that’s in clinical trials at the moment,” said Nisbet. “It increases brain delivery by about tenfold – 10 times more antibody can get to the brain, so you’re reducing the dose quite significantly, which should mean fewer side effects.”
Meanwhile, Nisbet is part of a research team trying to use mRNA to treat Alzheimer’s by targeting tau protein in two ways.
First, they are designing lipid particles that can house the mRNA and help it cross the blood-brain barrier. Once in the brain, this mRNA acts like an instruction manual for the brain, telling it which antibodies to make to target tau. Second, they are trying to develop an mRNA vaccine.
“The advantage of the vaccines is they are very cost-effective,” said Nisbet.
“We’ve estimated that a single dose would, at the maximum, cost about $50. And, like a true vaccine, you would only need a couple of doses, and then maybe a booster once a year.”






